Literature DB >> 21567089

Blockade of IGF-IR exerts anticancer effects in hepatocellular carcinoma.

Wei-Feng Yao1, Jun-Wei Liu, Guo-Liang Sheng, Dong-Sheng Huang.   

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, and is characterized by a high degree of malignancy and a low survival rate. Most HCCs express insulin-like growth factors and their receptors (IGF-IR), which mediate signaling, promote survival and invasion, and prevent apoptosis. Thus, they may be potential targets for the treatment of HCCs. In the present study, the potential therapeutic effect of Tyrphostin AG1024 in HCC was examined. After treatment with various concentrations of AG1024 (one selective inhibitor of IGF-IR), AG1024 not only dose-dependently inhibited the proliferation of HCC cells and induced apoptosis, but also markedly inhibited invasion ability. Expression of proteins detected by Western blot analysis revealed that AG1024 dose-dependently increased the expression of cytochrome C, while procaspase-3 and phospho-ERK were down-regulated. Thus, IGF-IR inhibition may be a promising novel approach to the treatment of HCC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21567089     DOI: 10.3892/mmr.2011.486

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  10 in total

Review 1.  Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.

Authors:  Mónica Enguita-Germán; Puri Fortes
Journal:  World J Hepatol       Date:  2014-10-27

Review 2.  Hepatitis C virus-mediated angiogenesis: molecular mechanisms and therapeutic strategies.

Authors:  Mohamed Hassan; Denis Selimovic; Abdelouahid El-Khattouti; Martine Soell; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader; Mosaad Megahed
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

3.  Overexpression of insulin-like growth factor-I receptor as a pertinent biomarker for hepatocytes malignant transformation.

Authors:  Xiao-Di Yan; Min Yao; Li Wang; Hai-Jian Zhang; Mei-Juan Yan; Xing Gu; Yun Shi; Jie Chen; Zhi-Zhen Dong; Deng-Fu Yao
Journal:  World J Gastroenterol       Date:  2013-09-28       Impact factor: 5.742

Review 4.  Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

5.  MicroRNA-495 suppresses cell proliferation and invasion of hepatocellular carcinoma by directly targeting insulin-like growth factor receptor-1.

Authors:  Ying Ye; Juhua Zhuang; Guangdong Wang; Saifei He; Suiliang Zhang; Guoyu Wang; Jing Ni; Jiening Wang; Wei Xia
Journal:  Exp Ther Med       Date:  2017-11-08       Impact factor: 2.751

6.  microRNA-944 inhibits the malignancy of hepatocellular carcinoma by directly targeting IGF-1R and deactivating the PI3K/Akt signaling pathway.

Authors:  Lili Lv; Xiaodong Wang; Tonghui Ma
Journal:  Cancer Manag Res       Date:  2019-03-29       Impact factor: 3.989

7.  Effects of targeted-edited oncogenic insulin-like growth factor-1 receptor with specific-sgRNA on biological behaviors of HepG2 cells.

Authors:  Min Yao; Yin Cai; Zhi-Jun Wu; Ping Zhou; Wen-Li Sai; De-Feng Wang; Li Wang; Deng-Fu Yao
Journal:  World J Clin Cases       Date:  2022-10-06       Impact factor: 1.534

Review 8.  Emerging role of insulin-like growth factor-binding protein 7 in hepatocellular carcinoma.

Authors:  Maaged Akiel; Devaraja Rajasekaran; Rachel Gredler; Ayesha Siddiq; Jyoti Srivastava; Chadia Robertson; Nidhi Himanshu Jariwala; Paul B Fisher; Devanand Sarkar
Journal:  J Hepatocell Carcinoma       Date:  2014-03-26

Review 9.  Type I insulin-like growth factor receptor signaling in hematological malignancies.

Authors:  Deeksha Vishwamitra; Suraj Konnath George; Ping Shi; Ahmed O Kaseb; Hesham M Amin
Journal:  Oncotarget       Date:  2017-01-03

10.  AG-1024 Sensitizes Sorafenib-Resistant Hepatocellular Carcinoma Cells to Sorafenib via Enhancing G1/S Arrest.

Authors:  Wei Zhou; Weiyang Lou; Junru Chen; Bisha Ding; Binjie Chen; Haiyang Xie; Lin Zhou; Shusen Zheng; Donghai Jiang
Journal:  Onco Targets Ther       Date:  2021-02-15       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.